Why MDxHealth SA’s (MDXH) Stock Is Down 10.30%
As of Friday, May 15, MDxHealth SA’s MDXH share price has dipped by 10.30%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company’s testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient’s previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient’s infection. It offers genomic prostate score, which provides personalized genomic insights to physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. The company sells its products through urology sales force consisting of direct sales representatives, strategic account managers, and regional sales managers. The company has a collaboration the initiation of Genomic Prostate Score (GPS) testing. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Commentary & Analysis
Why MDxHealth SA’s (MDXH) Stock Is Down 10.90%
As of Friday, May 15, MDxHealth SA’s MDXH share price has dipped by 10.90%, which has investors questioning if this is right time to buy.Jenna Brashear
Why MDxHealth SA’s (MDXH) Stock Is Down 49.24%
As of Thursday, May 14, MDxHealth SA’s MDXH share price has dipped by 49.24%, which has investors questioning if this is right time to buy.Jenna Brashear
Why MDxHealth SA’s (MDXH) Stock Is Down 47.95%
As of Thursday, May 14, MDxHealth SA’s MDXH share price has dipped by 47.95%, which has investors questioning if this is right time to buy.Tudor Pop
Why MDxHealth SA’s (MDXH) Stock Is Up 5.35%
As of Wednesday, May 13, MDxHealth SA’s MDXH share price has surged by 5.35%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | MDXH | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $67.7 | $288.9 | 18% |
|
| Shares Out (Mil) | 52.5 | 54.0 | 49% |
|
| Institutional Ownership | 87.1% | 93.1% | 55% |
|
| Float (Mil) | 79.0 | 41.4 | 57% |
|
| Beta | na | 0.94 | na |
|
| Avg Daily Volume (000s) | 313 | 480 | 52% |
|
| Price Change (52-week) |
(80.3%) | 59.9% | 7% |
|
| Growth | MDXH | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 42.3% | 14.1% | 94% |
|
| Net Income (5yr) | (3.1%) | (10.1%) | 36% |
|
| EPS (5yr) | 27.9% | 15.9% | 79 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 13.2% | (15.6%) | 71% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | MDXH | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $108 | $37 | 27% |
|
| Net Income (TTM) (Mil) | ($34) | ($43) | 19% |
|
| EPS (TTM) | ($0.671) | ($1.500) | 25% |
|
| Operating Cash Flow (TTM) (Mil) | ($2) | ($31) | 29% |
|
| Net Cash Flow (TTM) (Mil) | ($9) | $2 | 31% |
|
| Long-Term Debt (Q1) (Mil) | $85 | $4 | 43% |
|
| Enterprise Value (Q1) (Mil) | $234 | $190 | 27% |
|
| Valuation | MDXH | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.84 | na |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | MDXH | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 62.9% | 66.9% | 75% |
|
| Net Margin | (32.7%) | (74.2%) | 14% |
|
| ROA | (23.1%) | (47.7%) | 19% |
|
| ROE | (460.3%) | (55.0%) | 1% |
|
| Liabilities to Assets | 108.2% | 29.6% | 95% |
|
| F-Score | 4 | 3 | 33% |
|
MDxHealth SA did not pass any screens on 9/2/2026.
